(S)-N-Benzenesulfonyl-2-hydroxymethylpyrrolidine | 122030-80-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-N-Benzenesulfonyl-2-hydroxymethylpyrrolidine
• 英文别名: (S)-(N-benzenesulfonyl)prolinol；[(2S)-1-(benzenesulfonyl)pyrrolidin-2-yl]methanol
• CAS: 122030-80-2
• 化学式: C₁₁H₁₅NO₃S
• 分子量: 241.311
• InChiKey: VDRGQWKLTZSRAY-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (S)-N-Benzenesulfonyl-2-hydroxymethylpyrrolidine 在 三乙烯二胺 、 草酰氯 、 二甲基亚砜 作用下， 反应 13.5h， 生成
  参考文献：
  名称：

  Manickum, Thavrin; Ross, Gregory H. P., South African Journal of Chemistry, 1994, vol. 47, # 1, p. 1 - 16

  摘要：

  DOI：
• 作为产物：
  描述：

  N-苯磺酰基-L-脯氨酸 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以65%的产率得到(S)-N-Benzenesulfonyl-2-hydroxymethylpyrrolidine
  参考文献：
  名称：

  Manickum, Thavrin; Ross, Gregory H. P., South African Journal of Chemistry, 1994, vol. 47, # 1, p. 1 - 16

  摘要：

  DOI：

文献信息

• [EN] METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE LA MÉTHYLAMINE COMME INHIBITEURS DE LA LYSYL OXIDASE POUR LE TRAITEMENT DU CANCER
  申请人：THE INST OF CANCER RESEARCH: ROYAL CANCER HOSPITAL

  公开号：WO2017141049A1

  公开（公告）日：2017-08-24

  Provided are compounds of the Formula (I), or a pharmaceutically acceptable salt thereof, wherein W, X, Y, Z, x, R1, R2, R3, x and n are defined in the specification. The compounds are inhibitors of lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family members (LOXL1, LOXL2, LOXL3, LOXL4) and are useful in therapy, particularly in the treatment of cancer. Also disclosed are LOX inhibitors for use in the treatment of a cancer associated with EGFR and biomarkers that predict responsiveness to a LOX inhibitor.

  提供的是Formula (I)的化合物，或其药用可接受的盐，其中W、X、Y、Z、x、R1、R2、R3、x和n在规范中有定义。这些化合物是赖氨酸氧化酶（LOX）和赖氨酸氧化酶样（LOXL）家族成员（LOXL1、LOXL2、LOXL3、LOXL4）的抑制剂，并且在治疗中很有用，特别是在癌症治疗中。还披露了用于治疗与EGFR相关的癌症的LOX抑制剂，以及预测对LOX抑制剂响应性的生物标志物。
• The remarkable effect of titanium tetraisopropoxide in diastereoselective reaction of carbaldehydes with chiral benzenesulfonamide lithium complexes.
  作者：Hiroshi TAKAHASHI、Takeshi TSUBUKI、Kimio HIGASHIYAMA

  DOI：10.1248/cpb.39.260

  日期：——

  Chiral benzenesulfonamide titanium ate-complexes (4 and 8) were prepared from the lithium complexes (2 and 6) by treatment with titanium tetraisopropoxide. The diastereoselective reactions of aromatic carbaldehydes with 4 and 8 were performed, and the chiral o-(1-aryl-1-hydroxymethyl)benzenesulfonamides (3a-d and 7a-e) were obtained in 80-87% yields. The diastereomeric excesses (d.e.) of these products were evaluated as 62-82%. These compounds were also prepared from the lithium complexes (2 and 6), but the d.e. values were only 6-14% in this case.

  通过用四异丙氧基钛处理锂络合物（2和6）制备手性苯磺酰胺钛酸酯络合物（4和8）。芳香族甲醛与4和8进行非对映选择性反应，得到手性邻-(1-芳基-1-羟甲基)苯磺酰胺(3a-d和7a-e)，收率80-87%。这些产品的非对映体过量 (d.e.) 经评估为 62-82%。这些化合物也是由锂配合物（2 和 6）制备的，但 d.e.在这种情况下，该值仅为 6-14%。
• COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN
  申请人：GLOBAL BLOOD THERAPEUTICS, INC.

  公开号：US20160083343A1

  公开（公告）日：2016-03-24

  Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

  本文提供了适用于调节血红蛋白的化合物和药物组合物，它们的制备方法和中间体，以及它们在治疗由血红蛋白介导的疾病和需要组织和/或细胞氧合的疾病中的使用方法。
• Compounds and uses thereof for the modulation of hemoglobin
  申请人：Global Blood Therapeutics, Inc.

  公开号：US10450269B1

  公开（公告）日：2019-10-22

  Provided herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

  本文提供了适合作为血红蛋白调节剂的化合物和药物组合物、制备它们的方法和中间体，以及将它们用于治疗由血红蛋白介导的疾病和可从组织和/或细胞氧合中获益的疾病的方法。
• Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer
  申请人：The Institute of Cancer Research: Royal Cancer Hospital

  公开号：US10807974B2

  公开（公告）日：2020-10-20

  Provided are compounds of the Formula (I), or a pharmaceutically acceptable salt thereof: wherein W, X, Y, Z, x, R1, R2, R3, x and n are defined in the specification. The compounds are inhibitors of lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family members (LOXL1, LOXL2, LOXL3, LOXL4) and are useful in therapy, particularly in the treatment of cancer. Also disclosed are LOX inhibitors for use in the treatment of a cancer associated with EGFR and biomarkers that predict responsiveness to a LOX inhibitor.

  所提供的是式 (I) 化合物或其药学上可接受的盐： 其中 W、X、Y、Z、x、R1、R2、R3、x 和 n 在说明书中定义。这些化合物是赖氨酰氧化酶（LOX）和赖氨酰氧化酶样（LOXL）家族成员（LOXL1、LOXL2、LOXL3、LOXL4）的抑制剂，可用于治疗，特别是癌症的治疗。还公开了用于治疗与表皮生长因子受体相关的癌症的 LOX 抑制剂，以及预测对 LOX 抑制剂反应性的生物标记物。